Scott Tarriff - 16 May 2023 Form 4 Insider Report for EAGLE PHARMACEUTICALS, INC. (EGRX)

Signature
/s/ Scott Tarriff
Issuer symbol
EGRX
Transactions as of
16 May 2023
Net transactions value
-$299,700
Form type
4
Filing time
18 May 2023, 17:22:57 UTC
Previous filing
15 May 2023
Next filing
04 Oct 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EGRX Common Stock Sale $299,700 -15,000 -2.5% $19.98 587,311 16 May 2023 Direct F1, F2
holding EGRX Common Stock 992,623 16 May 2023 By Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.7454 to $20.53 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 This report reflects an adjustment to the Reporting Person's direct holdings to exclude shares incorrectly included in prior reports as directly held and to reflect such shares as held indirectly through the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the "Trust").
F3 The shares are held by the Trust for the benefit of the Reporting Person's spouse and children. The Reporting Person does not have investment control over the shares held by the Trust and disclaims beneficial ownership of the shares, except to any pecuniary interest therein, if any.